The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...
A nationwide RECOVER study led by The University of Texas Health Science Center at San Antonio, funded by the National Institutes of Health, finds that females are at 31% more risk for long COVID.